Valo health and novo nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

BagsvÆrd, denmark and lexington, massachusetts, us, 8 january 2025 – novo nordisk a/s and valo health, inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on valo's extensive human dataset and computation powered by artificial intelligence (ai).
NVO Ratings Summary
NVO Quant Ranking